BioMarin Pharmaceutical Inc. - General Releases
BioMarin Pharmaceutical Inc. - General Releases
BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease
Posted: May 27, 2014, 1:30 pm
BioMarin to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference on May 14th and the UBS Global Healthcare Conference on May 20th
Posted: May 6, 2014, 1:30 pm
BioMarin Announces First Quarter 2014 Financial Results and VIMIZIM(TM) Launch Progress
Posted: May 1, 2014, 1:30 pm
BioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages
Posted: April 28, 2014, 1:30 pm
BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET
Posted: April 16, 2014, 1:30 pm
FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets
Posted: April 14, 2014, 1:30 pm
BioMarin Appoints Pioneer in Personalized Medicine, Dennis J. Slamon, M.D., Ph.D., to Board of Directors
Posted: March 21, 2014, 1:30 pm
BioMarin Announces Pricing of Public Offering of Common Stock
Posted: March 5, 2014, 2:30 pm
BioMarin Announces Public Offering of Common Stock
Posted: March 4, 2014, 2:30 pm
BioMarin to Present at the Barclays Global Healthcare Conference in Miami
Posted: March 4, 2014, 2:30 pm